BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-182@pharmaconomics
DTSTAMP:20260707T030110Z
DTSTART;VALUE=DATE:20260320
DTEND;VALUE=DATE:20260321
SUMMARY:RYTM PDUFA — setmelanotide
DESCRIPTION:The FDA's approval decision on setmelanotide for acquired hypothalamic obesity is due Mar 20\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/ex992rytm20260313emanate.htm\n\nTrack it: https://pharmaconomics.com/e/182
URL:https://pharmaconomics.com/e/182
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RYTM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR